EUVIMEDEUVIMED entdecken
Crossref

Risk of secondary T-cell malignancy after CAR T-cell therapy

Drug and Therapeutics Bulletin · 2025

DOI: 10.1136/dtb.2025.000023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Therapeutics Bulletin, 2025. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Second Primary, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overview of: European Medicines Agency. CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin [online], 2024. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024 [Accessed 22 May 2025].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveNeoplasms, Second PrimaryReceptors, Chimeric AntigenT-LymphocytesHumansPharmacovigilanceRisk Assessment

Stichwörter der Autor:innen

Drug-Related Side Effects and Adverse ReactionsHealth Care Quality, Access, and Evaluation

Substanzen

Receptors, Chimeric Antigen

Zitieren

APA

(2025). Risk of secondary T-cell malignancy after CAR T-cell therapy. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2025.000023

Vancouver

Risk of secondary T-cell malignancy after CAR T-cell therapy. Drug and Therapeutics Bulletin. 2025. doi:10.1136/dtb.2025.000023

BibTeX
@article{euvimed2025,
  title = {Risk of secondary T-cell malignancy after CAR T-cell therapy},
  journal = {Drug and Therapeutics Bulletin},
  year = {2025},
  doi = {10.1136/dtb.2025.000023}
}
Kostenlos starten →